Related Experiment Video
Updated: Sep 20, 2026

Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Pseudomyxoma peritonei: the 'controversial' disease
Abstract:
Pseudomyxoma peritonei (PMP) is a rare disease that is characterized by a large amount of mucinous ascites with peritoneal and omental implants. The etiology of the disease remains unclear. Histologically, two main categories have been described: disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis (PMCA). It is commonly diagnosed incidentally at laparotomy. Most investigators agree that radical surgical debulking and appendectomy are the cornerstone of treatment, but the optimal management of the disease remains controversial. The role of intraoperative and intraperitoneal chemotherapy has been evaluated by a number of authors. The clinical outcomes vary widely between the benign and the malignant forms and between the different treatment modalities. We discuss the pathology, origin, clinical presentation, diagnosis, treatment, and prognosis of PMP.
Insights
Pseudomyxoma peritonei (PMP) is a rare condition causing mucinous ascites and implants. Treatment involves surgical debulking, but optimal management and outcomes for PMP remain under investigation.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Pseudomyxoma peritonei (PMP) is a rare condition characterized by mucinous ascites and peritoneal/omental implants.
- Its etiology is unclear, with two histological subtypes: disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis (PMCA).
- Diagnosis is often incidental during laparotomy.
Purpose of the Study:
- To provide a comprehensive overview of Pseudomyxoma Peritonei.
- To discuss the pathology, origin, clinical presentation, diagnosis, treatment, and prognosis of PMP.
- To highlight the controversies in optimal management strategies.
Main Methods:
- Review of existing literature on Pseudomyxoma Peritonei.
- Discussion of histological classifications (DPAM vs. PMCA).
- Analysis of treatment modalities including surgical debulking and chemotherapy.
Main Results:
- PMP presents with variable clinical outcomes depending on histological type and treatment.
- Radical surgical debulking and appendectomy are considered primary treatments.
- The efficacy of intraoperative and intraperitoneal chemotherapy is under evaluation.
Conclusions:
- Pseudomyxoma Peritonei management requires a multidisciplinary approach.
- Further research is needed to clarify optimal treatment protocols and improve patient outcomes.
- Understanding the distinction between DPAM and PMCA is crucial for prognosis.
Related Concept Videos
Diverticular Disease of the Colon
Appendicitis
Appendicitis-I: Introduction
Etiology: Appendicitis can arise from various causes, primarily rooted in the obstruction of the appendix lumen. Factors contributing to this obstruction include fecal accumulation, lymphoid hyperplasia and, in...
